文献速递肝病消化内镜

肝细胞来源细胞外囊泡经microRNA-1促进内皮炎症与动脉粥样硬化

Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1.
PubMed 文献 · J Hepatol · 2019-09-27

本研究探讨非酒精性脂肪性肝病(NAFLD)中肝细胞来源细胞外囊泡(EVs)在内皮炎症和动脉粥样硬化中的作用。脂肪变性肝细胞释放更多EVs,其miRNA谱改变,通过递送miR-1抑制KLF4并激活NF-κB,促进内皮炎症;抑制miR-1可减轻ApoE缺陷小鼠的动脉粥样硬化。

要点

  • 脂肪变性肝细胞释放更多EVs,其miRNA表达谱显著改变。
  • EVs通过递送miR-1抑制KLF4、激活NF-κB,诱导内皮炎症。
  • 抑制miR-1可减轻ApoE缺陷小鼠的动脉粥样硬化。

核心结论

  • 脂肪变性肝细胞来源EVs通过递送miR-1、抑制KLF4和激活NF-κB,促进内皮炎症并加剧动脉粥样硬化。

研究设计与样本

  • 从脂肪变性肝细胞分离、定量和表征EVs,使用内皮细胞特异性PCR阵列筛选功能,并进行全局miRNA表达谱分析。
  • 在载脂蛋白E(ApoE)缺陷小鼠中给予miR-1特异性抑制剂antagomiR-1,研究miR-1对动脉粥样硬化的体内效应。

主要发现

  • 脂肪变性肝细胞释放更多EVs,且其miRNA表达谱与对照肝细胞来源EVs显著不同。
  • 内皮细胞与脂肪变性肝细胞共培养,或经其EVs或miR-1处理,促炎分子表达显著增加,NF-κB活性升高,KLF4表达降低。
  • 下调或抑制miR-1可阻止EV诱导的内皮炎症;过表达KLF4可显著消除miR-1诱导的内皮炎症。
  • miR-1抑制剂不仅在体外减少内皮炎症,还在ApoE缺陷小鼠中减轻动脉粥样硬化。

临床怎么用

  • 提示肝细胞来源EVs及其miR-1货物可能作为NAFLD相关心血管疾病的干预靶点。
  • miR-1抑制剂在动物模型中减轻动脉粥样硬化,但尚未转化至临床。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Clinical evidence has indicated a close link between non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). However, the underlying mechanism remains to be elucidated. This study aimed to explore a potential role of hepatocyte-derived extracellular vesicles (EVs) in endothelial inflammation and atherogenesis in the context of NAFLD. METHODS: EVs were isolated, quantified and characterized from steatotic hepatocytes. An endothelial cell-specific PCR array was used to screen the functional properties of EVs. Profiling of global microRNA expression was conducted in EVs. The expression level and biological function of microRNA-1 (miR-1) was determined by quantitative PCR, immunoblot and reporter gene assays, respectively. The in vivo effect of miR-1 on atherogenesis was investigated in apolipoprotein E (ApoE)-deficient mice administered with a miR-1-specific inhibitor, antagomiR-1. RESULTS: Steatotic hepatocytes released more EVs, which had significantly altered miRNA expression profiles compared to the EVs released by control hepatocytes. Endothelial cells co-cultured with steatotic hepatocytes, or treated with their EVs or miR-1, expressed significantly more proinflammatory molecules, as well as exhibiting increased NF-κB activity and reduced Kruppel-like factor 4 (KLF4) expression. EV-induced endothelial inflammation was prevented by either downregulation or inhibition of miR-1. While miR-1 treatment suppressed KLF4 expression and reporter gene activity, overexpression of KLF4 dramatically abolished the miR-1-induced endothelial inflammation. Moreover, not only did the miR-1 inhibitor reduce endothelial inflammation in vitro, but it also attenuated atherogenesis in ApoE-deficient mice. CONCLUSION: Steatotic hepatocyte-derived EVs promote endothelial inflammation and facilitate atherogenesis by miR-1 delivery, KLF4 suppression and NF-κB activation. The findings illustrate an important role of hepatocyte-derived EVs in distant communications between the liver and vasculature, suggesting a new mechanism underlying the link between NAFLD and CVD. LAY SUMMARY: Non-alcoholic fatty liver disease (NAFLD), a condition highly prevalent in obese and/or diabetic patients, is emerging as an independent risk factor of cardiovascular disease. Herein, we demonstrated that extracellular vesicles, released by hepatocytes under NAFLD conditions, cause vascular endothelial inflammation and promote atherosclerosis. Within these toxic vesicles, we identified a small molecular cargo that acted as a potent inducer of endothelial inflammation. By inhibiting this cargo's function, a specific gene-based inhibitor profoundly attenuated atherogenesis in mice, uncovering a novel mechanism which may be used to prevent or treat cardiovascular disease in patients with NAFLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Jiang F, Chen Q, Wang W, et al. Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1. J Hepatol. 2019. PMID: 31568800. doi:10.1016/j.jhep.2019.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。